In vivo evaluation of an adenoviral vector encoding canine factor VIII: High-level, sustained expression in hemophiliac mice

Human Gene Therapy

Volumn 10, Issue 11, 1999, Pages 1791-1802

  Gallo Penn, Angela M ^a   Shirley, Pamela S ^a   Andrews, Julie L ^a   Kayda, Dawn B ^a   Pinkstaff, Anne M ^a   Kaloss, Michele ^a   Tinlin, Shawn ^b   Cameron, Cherie ^b   Notley, Colleen ^b   Hough, Christine ^b   Lillicrap, David ^b   Kaleko, Michael ^a   Connelly, Sheila ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BLOOD CLOTTING; DOG; GENE EXPRESSION; GENE ISOLATION; GENE THERAPY; GENETIC TRANSDUCTION; HEMOPHILIA A; IMMUNOGENICITY; LIVER TOXICITY; MOUSE; NONHUMAN; PHENOTYPE;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DOGS; EVALUATION STUDIES; FACTOR VIII; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; MAMMALIA;

EID: 0033587552     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017473     Document Type: Article

References (53)

1. BI, L., LAWLER, A.M., ANTONARAKIS, S.E., HIGH, K.A., GERHART, J.D., and KAZAZIAN, H.H. (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genet. 10, 119-121.
2. BOWIE, E.J.W., OWEN, C.A.J., and GILES, A.R. (1989). Animal models for the study of factor VIII and von Willebrand factor. In Coagulation and Bleeding Disorders: The Role of Factor VIII and von Willebrand Factor. T.S. Zimmerman and Z.M. Ruggerieds, eds. (Marcel Dekker, New York) pp. 305-324.
3. BRANN, T., KAYDA, D., LYONS, R., SHIRLEY, P., ROY, S., KALEKO, M., and SMITH, T.A.G. (1999). Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Submitted.
4. CAMERON, C., NOTLEY, C., HOYLE, S., McGLYNN, L., HOUGH, C., KAMISUE, S., GILES, A.R., and LILLICRAP, D. (1998). The canine factor VIII cDNA and 5′ flanking sequence. Thromb. Haemost. 79, 317-322.
5. CONNELLY, S., and KALEKO, M. (1997). Gene therapy for hemophilia A. Thromb. Haemost. 78, 31-36.
6. CONNELLY, S., and KALEKO, M. (1998). Haemophilia A gene therapy. Haemophilia 4, 380-388.
7. CONNELLY, S., SMITH, T.A.G., DHIR, G., GARDNER, J.M., MEHAFFEY, M.G., ZARET, K.S., McCLELLAND, A., and KALEKO, M. (1995). In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6, 185-193.
8. CONNELLY, S., GARDNER, J.M., LYONS, R.M., McCLELLAND, A., and KALEKO, M. (1996a). Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87, 4671-4677.
9. CONNELLY, S., GARDNER, J.M., McCLELLAND, A., and KALEKO, M. (1996b). High level tissue-specific expression of functional human FVIII in mice. Hum. Gene Ther. 7, 183-195.
10. CONNELLY, S., MOUNT, J., MAUSER, A., GARDNER, J.M., KALEKO, M., McCLELLAND, A., and LOTHROP, C.D. (1996c). Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 88, 3846-3853.
11. CONNELLY, S., ANDREWS, J., GALLO, A.M., QIAN, J., HOYER, L., KADAN, M.J., GORZIGLIA, M.I., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281.
12. CONNELLY, S., ANDREWS, J., GALLO-PENN, A.M., TAGLI-AVACCA, L., KAUFMAN, R.J., and KALEKO, M. (1999). Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Thromb. Haemost. 81, 234-239.
13. DIMICHELE, D. (1996). Hemophilia 1996. New approach to an old disease. Pediatr. Clin. North Am. 43, 709-736.
14. EATON, D.L., WOOD, W.I, EATON, D., HASS, P.E., HOLLINGSHEAD, P., WION, K., MATHER, J., LAWN, R.M., VEHAR, G.A., and GORMAN, C. (1986). Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25, 1-2.
15. ELDER, B., LAKICH, D., and GITSCHIER, J. (1993). Sequence of the murine factor VIII cDNA. Genomics 16, 374-379.
16. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994a). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5, 1217-1229.
17. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994b). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
18. FEINGOLD, H.M., PIVACEK, L.E., MELARAGNO, A.J., and VARERI, C.R. (1986). Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am. J. Vet. Res. 47, 2197-2199.
19. GILES, A.R., TINLIN, S., and GREENWOOD, R. (1982). A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60, 727-730.
20. GILES, A.R., TINLIN, S., HOOGENDOORN, H., FOURNEL, M.A., NG, P., and PANCHAM, N. (1988). In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood 72, 335-339.
21. GITSCHIER, J., WOOD, W.I., GORALKA, T.M., WION, K.L., CHEN, E.Y., EATON, D.H., VEHAR, G.A., CAPON, D.J., and LAWN, R.M. (1984). Characterization of the human factor VIII gene. Nature (London) 312, 326-330.
22. GORZIGLIA, M.I., KADAN, M.J., YEI, S., LIM, J., LEE, G.M., LUTHRA, R., and TRAPNELL, B.C. (1996). Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 6, 4173-4178.
23. GRAHAM, J.B., BUCKWALTER, J.A., HARTLEY, L.J., and BRINKHOUS, K.M. (1949). Canine hemophilia: Observations on the course, the clotting anomaly, and the effects of blood transfusion. J. Exp. Med. 90, 97-102.
24. HAY, C., and LOZIER, J.N. (1995). Porcine factor VIII therapy in patients with factor VIII inhibitors. In Inhibitors to Coagulation Factors. L.W. Hoyer, J.M. Lusher, H.M. Reisner, and G.C. White, eds. (Plenum, New York) pp. 143-153.
25. HEALEY, J.F., LUBIN, I.M., and LOLLAR, P. (1996). The cDNA and derived amino acid sequence of porcine factor VIII. Blood 88, 4209-4214.
26. HOEBEN, R.C., FALLAUX, F.J., CRAMER, S.J., VAN DEN WOLLENBERG, J.M., VAN ORMONDT, H., BRIET, E., and VAN DER EB, A.J. (1995). Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 85, 2447-2454.
27. HORTON, R.M., CAI, Z., HO, S.N., and PEASE, L.R. (1990). Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. BioTechniques 8, 528-535.
28. HOYER, L.W. (1994). Hemophilia A. N. Engl. J. Med. 330, 38-47.
29. KARGES, H.E., FUNK, K.A., and RONNEBERGER, H. (1994). Activity of coagulation and fibrinolysis parameters in animals. Arzneimittelforschung 44, 793-797.
30. KAUFMAN, R.J., WASLEY, L.C., DAVIES, M.V., WISE, R.J., ISRAEL, D.I., and DORNER, A.I. (1989). Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol. Cell Biol. 9, 1233-1242.
31. KINGDON, H.S., and HASSELL, T.M. (1981). Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood 58, 969.
32. KNOWLES, B.B., HOWE, C.C., and ADEN, D.P. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209, 497-499.
33. KOEBERL, D.D., HALBERT, C.L., KRUMM, A., and MILLER, A.D. (1995). Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum. Gene Ther. 6, 469-479.
34. KOSTER, T., BLANN, A.D., BRIET, E., VANDENBROUCKE, J.P., and ROSENDAAL, F.R. (1995). Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155.
35. LITTLEWOOD, J.D., and BARROWCLIFFE, T.W. (1987). The development and characterisation of antibodies to human factor VIII in haemophilic dogs. Thromb. Haemost. 57, 314-321.
36. LOLLAR, P., PARKER, E.T., and FAY, P.J. (1992). Coagulant properties of hybrid human/porcine factor VIII molecules. J. Biol. Chem. 267, 23652-23654.
37. LYNCH, C.M., ISRAEL, D.I., KAUFMAN, R.J., and MILLER, A.D. (1993). Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum. Gene Ther. 4, 259-272.
38. MERTENS, K., BRIET, E., and GILES, A.R. (1990). The role of factor VII in haemostasis: Infusion studies of factor VIIa in a canine models of factor VIII deficiency. Thromb. Haemost. 64, 138-144.
39. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
40. NICHOLS, T., BELLINGER, D.A., REDDICK, R.L., SMITH, S.V., KOCH, G.G., DAVIS, K., SIGMAN, I., BRINKHOUS, K.M., GRIGGS, T.R., and READ, M.S. (1993). The roles of von Willebrand factor and factor VIII in arterial thrombosis: Studies in canine von Willebrand disease and hemophilia A. Blood 81, 2644-2651.
41. O'DONNELL, J., TUDDENHAM, E.G., MANNING, R., KEMBALLCOOK, G., JOHNSON, D., and LAFFAN, M. (1997). High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction. Thromb. Haemost. 77, 825-828.
42. PIPE, S.W., MORRIS, J.A., SHAH, J., and KAUFMAN, R.J. (1998). Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J. Biol. Chem. 273, 8537-8544.
43. PITTMAN, D.D., ALDERMAN, E.M., TOMKINSON, K.N., WANG, J.H., GILES, A.R., and KAUFMAN, R.J. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81, 2925-2935.
44. QUIMBY, F.W. (1989). The mouse. In The Clinical Chemistry of Laboratory Animals. W.F. Loeb and F.W. Quimby, eds. (Pergamon Press, Oxford) pp. 3-18.
45. SMITH, T.A.G. (1997). Gene therapy for haemophilia. Exp. Opin. Invest. Drugs 6, 1685-1690.
46. SMITH, T.A.G., MEHAFFEY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1993). Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397-402.
47. SWAROOP, M., MOUSSALLI, M., PIPE, S.W., and KAUFMAN, R.J. (1997). Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J. Biol. Chem. 272, 24121-24124.
48. TINLIN, S., WEBSTER, S., and GILES, A.R. (1993). The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb. Haemost. 69, 21-24.
49. TOLSTOSHEV, P., MITTEREDER, N., YEI, S., and TRAPNELL, B.C. (1994). Adenovirus vectors for gene therapy. In Cancer Chemotherapy: Challenges for the Future. (Anonymous Excerpta Medica, Tokyo, Japan) pp. 23-31.
50. TOOLE, J.J., KNOPF, J.L., WOZNEY, J.M., SULTZMAN, P.A., BUECKER, J., PITTMAN, D.D., KAUFMAN, R.J., BROWN, E., SHOEMAKER, C., ORR, E.C., AMPHLETT, G.W., FOSTER, W.B., COE, M.L., KNUTSON, G.J., FASS, D.N., and HEWICK, R.M. (1984). Molecular cloning of a cDNA encoding antihemophiliac factor. Nature (London) 312, 342-346.
51. TOOLE, J.J., PITTMAN, D.D., ORR, E.C., MURTHA, P., WASLEY, L.C., and KAUFMAN, R.J. (1986). A large region (∼95 kDa of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U.S.A. 83, 5939-5942.
52. WOOD, W.I., CAPON, D.J., SIMONSEN, C.C., EATON, D.L., GITSCHIER, J., KEYT, B., SEEBURG, P.H., SMITH, D.H., HOLLINGSHEAD, P., WION, K.L., DELWART, E., TUDDENHAM, E.G.D., VEHAR, G.A., and LAWN, R.M. (1984). Expression of active human factor VIII from recombinant DNA cloned. Nature (London) 312, 330-337.
53. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.